Adcendo
Stub active Updated Apr 14, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
Founders
About
Adcendo is a Copenhagen-based clinical-stage biotechnology company developing first- and best-in-class antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical need 1. The company also has operations in Boston, Massachusetts 1. Adcendo is advancing three ADC programs targeting tissue factor, uPARAP, and an undisclosed target in solid tumors including head and neck cancer, pancreatic cancer, colorectal cancer, and sarcoma 1.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-14 | Series C | $75M | Jeito Capital | Vida Ventures, BPI France, EIFO, TCGX, RA Capital Management, TPG, Orbimed, Venrock, Surveyor, Logos Capital, Novo Holdings, Pontifax Venture Capital, Dawn Biopharma, HealthCap, Gilde Healthcare, Ysios Capital 1 |
What Investors Say
No verified investor quotes available at this time.
What Founders Say
No verified founder quotes available at this time.
Sources
-
PR Newswire, “Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline,” April 14, 2026. https://www.prnewswire.com/news-releases/adcendo-aps-completes-75-million-series-c-financing-to-continue-advancing-first–and-best-in-class-clinical-adc-pipeline-302740749.html↩↩↩↩